Literature DB >> 12401804

PAX3-FKHR transformation increases 26 S proteasome-dependent degradation of p27Kip1, a potential role for elevated Skp2 expression.

Lei Zhang1, Chiayeng Wang.   

Abstract

PAX3-FKHR is an oncogenic form of the developmental regulator Pax3 transcription factor. PAX3-FKHR results from a t(2,13) chromosomal translocation, a unique genetic marker of alveolar rhabdomyosarcoma. In this study, we showed that ectopic expression of PAX3-FKHR, but not Pax3, in fibroblasts altered cell cycle control and accelerated G(0)/G(1) to S cell cycle transition. PAX3-FKHR-expressing cells had reduced expression of p27(Kip1) protein, a key cell cycle regulator. The reduction in p27(Kip1) levels by PAX3-FKHR resulted from destabilization of p27(Kip1) as shown by cycloheximide treatment and in vivo pulse-chase labeling experiments. The reduced p27(Kip1) protein level in PAX3-FKHR-expressing cells was restored to the level of control cells by treatment with chemical inhibitors that specifically blocked 26 S proteasome activity. Along with the reduction in p27(Kip1) protein, PAX3-FKHR-expressing cells exhibited elevated expression of F-box Skp2 protein, a substrate-specific component of SCF (Skp1-Cullin-F box protein) ligase involved in the cell cycle-dependent control of p27(Kip1) ubiquitination and 26 S proteasome dependent degradation. Finally, we showed that ectopic expression of p27(Kip1) in PAX3-FKHR-expressing cells significantly reduced the proliferation and colony-forming potential of these cells, implicating that down-regulation of p27(Kip1) protein played an active role in the PAX3-FKHR-directed cell transformation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12401804     DOI: 10.1074/jbc.M205424200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

Review 1.  New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer.

Authors:  Göran Stenman; Mattias K Andersson; Ywonne Andrén
Journal:  Cell Cycle       Date:  2010-08-28       Impact factor: 4.534

2.  FOXO1: a potential target for human diseases.

Authors:  Huarui Lu; Haojie Huang
Journal:  Curr Drug Targets       Date:  2011-08       Impact factor: 3.465

Review 3.  Childhood rhabdomyosarcoma: recent advances and prospective views.

Authors:  C Wang
Journal:  J Dent Res       Date:  2011-09-13       Impact factor: 6.116

4.  Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation.

Authors:  Haojie Huang; Kevin M Regan; Fang Wang; Diping Wang; David I Smith; Jan M A van Deursen; Donald J Tindall
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-24       Impact factor: 11.205

Review 5.  PAX3-FOXO1 fusion gene in rhabdomyosarcoma.

Authors:  Corinne M Linardic
Journal:  Cancer Lett       Date:  2008-05-23       Impact factor: 8.679

Review 6.  FOXOs, cancer and regulation of apoptosis.

Authors:  Z Fu; D J Tindall
Journal:  Oncogene       Date:  2008-04-07       Impact factor: 9.867

7.  Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma.

Authors:  Koichi Nishijo; Qing-Rong Chen; Lei Zhang; Amanda T McCleish; Andrea Rodriguez; Min Jung Cho; Suresh I Prajapati; Jonathan A L Gelfond; Gary B Chisholm; Joel E Michalek; Bruce J Aronow; Frederic G Barr; R Lor Randall; Marc Ladanyi; Stephen J Qualman; Brian P Rubin; Robin D LeGallo; Chiayeng Wang; Javed Khan; Charles Keller
Journal:  Cancer Res       Date:  2009-04-01       Impact factor: 12.701

8.  Curcumin inhibits the replication of enterovirus 71 in vitro.

Authors:  Ying Qin; Lexun Lin; Yang Chen; Shuo Wu; Xiaoning Si; Heng Wu; Xia Zhai; Yan Wang; Lei Tong; Bo Pan; Xiaoyan Zhong; Tianying Wang; Wenran Zhao; Zhaohua Zhong
Journal:  Acta Pharm Sin B       Date:  2014-07-24       Impact factor: 11.413

9.  PAX3 in neuroblastoma: oncogenic potential, chemosensitivity and signalling pathways.

Authors:  Wen-Hui Fang; Qiuyu Wang; Hong-Mei Li; Mashud Ahmed; Patricia Kumar; Shant Kumar
Journal:  J Cell Mol Med       Date:  2013-11-04       Impact factor: 5.310

10.  Rb1 loss modifies but does not initiate alveolar rhabdomyosarcoma.

Authors:  Ken Kikuchi; Eri Taniguchi; Hung-I Harry Chen; Matthew N Svalina; Jinu Abraham; Elaine T Huang; Koichi Nishijo; Sean Davis; Christopher Louden; Lee Ann Zarzabal; Olivia Recht; Ayeza Bajwa; Noah Berlow; Mònica Suelves; Sherrie L Perkins; Paul S Meltzer; Atiya Mansoor; Joel E Michalek; Yidong Chen; Brian P Rubin; Charles Keller
Journal:  Skelet Muscle       Date:  2013-11-25       Impact factor: 4.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.